trending Market Intelligence /marketintelligence/en/news-insights/trending/gupdx9ro7nbmainrhcylpw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Amicus Therapeutics raises $250M in senior notes offering

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Amicus Therapeutics raises $250M in senior notes offering

Amicus Therapeutics Inc. raised $250 million in a senior notes offering to refinance some of its existing debt.

The amount includes $25 million raised as a result of purchasers' decision to exercise their overallotment option.

The notes offer a 3% coupon, payable semiannually starting June 15, 2017, and are convertible into Amicus shares at an initial rate of $6.12 per share for every $1,000 principal note tendered.

The notes mature on Dec. 15, 2023, and help Amicus refinance $82.2 million of its debt. The remaining net proceeds will be used for general corporate purposes.

Goldman Sachs & Co., J.P. Morgan Securities LLC, BofA Merrill Lynch and Leerink Partners LLC acted as book runners of the offering, with Cowen and Co. acting as lead manager.